ReviewTissue barriers2026
Claudins in ovarian cancer: emerging biomarkers and therapeutic targets.
Review in Tissue barriers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ZBTB7A promotes malignant phenotypes in ovarian cancer through transcriptional activation of CRLF1.Oncology reports · 2026Article
- Biomarker-Driven Treatments for Ovarian Cancer: Moving Beyond HRD?International journal of women's health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tight junctions (TJ) comprise protein complexes that help with the movement of ions and molecules through the paracellular pathway, thus maintaining both epithelial and endothelial integrity. The TJ proteins are diverse and include claudins, occludins, tricellulins, cingulins, and junctional adhesion molecules (JAM). Claudins are transmembrane proteins that serve as critical components of TJs in epithelial and endothelial cells. The human genome comprises 23 claudin genes, with 27 transmembrane domains recognized in mammals. Ovarian cancer (OC) is the most lethal form of all gynecologic malignancies worldwide, characterized by poor prognosis and a recurrence rate of up to 75%. In OC, several claudins are overexpressed relative to normal ovarian tissue. These elevated expression observed among OC subtypes indicates their potential utility as diagnostic biomarkers. Claudins represent potential targets for innovative therapeutic strategies. Though their exact involvement in OC is still not well understood, they are believed to be crucial for cancer invasion and therapy resistance. Recent studies show that claudins are involved in the EMT pathway and ERK, enlightening the effect of claudins in drug resistance. Clostridium perfringens enterotoxin (CPE) demonstrates potential as a therapy targeting claudins, specifically claudin-3 and -4, which serve as receptors for this toxin. Despite these advancements, challenges remain in comprehensively understanding claudin functions and in the development of effective claudin-targeted therapies. This review consolidates existing knowledge regarding claudins in OC, focusing on their expression patterns, biological functions, diagnostic and prognostic significance, and therapeutic implications. A thorough understanding of claudins in OC establishes a basis for enhancing diagnostic, predictive, and therapeutic approaches, which may result in improved therapy outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.